Skip to main content
Equibles
KYMR logo

KYMR

Kymera Therapeutics, Inc.
$114.16 -5.08 (-4.26%) At close · Jul 8
Market Cap
$9.79B
Shares
82,257,588

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$114.16 Open$119.16 Day$114.03–119.83 52W$36.65–130.05 Avg vol 30d1.0M Short int10.0M · 12.1% float · 15.6d Short vol48% Last earningsApr 30, 2026 DataAug 2020–Jul 2026 Filing10-Q · Apr 30
Equibles Rating blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.57
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +47%
above
Price vs 50-day avg +29%
above
RSI (14) 67
neutral
MACD trend Positive
52-week position 83%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +54%
trailing
6-month return +54%
trailing
YTD return +47%
this year
Relative strength +47%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $88 › 200d $77 — 50d above 200d
Institutional flow Distributing
6 of 258 funds reported for Jun 30 · net -2.2K sh shares
Insider flow Distributing
Net -$179.9M over 90 days · 100% sells
Short interest Falling
12.11% of float · ▼ -1.4% MoM · 15.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
258 holders — near 3-yr high, broad support
Squeeze score 73
high risk · 0–100
Fundamentals
Weak
Revenue growth −17%
Y/Y
EPS growth −24%
Y/Y
Free cash flow $-234.3M
Balance sheet $357.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 64%
annualized · 1-yr
Max drawdown −28%
past year
ATR 5.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
Next earnings call
Jul 29, 2026 Est · unconfirmed · in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Apr 30, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +47% Bullish
      Price vs 50-day avg
      +29% Bullish
      RSI (14)
      67 Neutral
      MACD trend
      Positive Bullish
      52-week position
      83% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $88 › 200d $77 — 50d above 200d
      Institutional flow Distributing
      6 of 258 funds reported for Jun 30 · net -2.2K sh shares
      Insider flow Distributing
      Net -$179.9M over 90 days · 100% sells
      Short interest Falling
      12.11% of float · ▼ -1.4% MoM · 15.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      258 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $37 Now $114 · 83% 52-wk high $130
      vs 200-day avg +47% vs 50-day avg +29%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Cash, cash equivalents and marketable securities 1.6B as of December 31, 2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      KYMR
      Kymera Therapeutics, Inc.
      this stock
      		$9.79B +46.7% -16.7% — 12.1%
      ONC
      BeOne Medicines Ltd.
      		 $437.67B -0.6% +22179.2% 890.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $126.01B +9.9% +46.2% 29.5 1.8%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $70.03B -14.0% +20.8% 16.3 3.2%
      ARGX
      Argenx SE
      		 $56.84B +8.8% — — 2.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      256
      % held
      113.8%
      Reported
      6 of 258
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      335
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      10.0M
      Days to cover
      15.6d
      Change
      -140.9K sh
      View
      Short Volume
      Short vol %
      48%
      As of
      Jul 9, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.4K
      Value
      $174.7K
      As of
      Jun 8, 2026
      View
      Off-Exchange
      Off-exchange %
      50.0%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$179.9M
      Buyers / Sellers
      0 / 6
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $39.2M
      Net income (FY)
      $-311.4M
      EPS diluted
      $-3.69
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $6.0M
      Shares
      50.0K
      Filed
      Jul 7, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 3, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      KYMR -0.4% +54.4% +54.0% -0.4% +46.7%
      SPY -0.2% +0.8% +7.4% -0.2% +9.3%
      vs SPY -0.3% +53.5% +46.6% -0.3% +37.4%
      Key facts CIK 1815442 CUSIP 501575104 13F (30d) 9 filings 7 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)